PH12023552963A1 - Compositions and methods for the treatment of depression - Google Patents

Compositions and methods for the treatment of depression

Info

Publication number
PH12023552963A1
PH12023552963A1 PH1/2023/552963A PH12023552963A PH12023552963A1 PH 12023552963 A1 PH12023552963 A1 PH 12023552963A1 PH 12023552963 A PH12023552963 A PH 12023552963A PH 12023552963 A1 PH12023552963 A1 PH 12023552963A1
Authority
PH
Philippines
Prior art keywords
patient
treatment
methods
aticaprant
reuptake inhibitor
Prior art date
Application number
PH1/2023/552963A
Other languages
English (en)
Inventor
Wayne C Drevets
Srihari Gopal
Iva Kezic
Chakradhar Lagishetty
Rama Melkote
Darrel Pemberton
Vanina Popova
Adam Savitz
Mark Schmidt
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PH12023552963A1 publication Critical patent/PH12023552963A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH1/2023/552963A 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression PH12023552963A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
PH12023552963A1 true PH12023552963A1 (en) 2024-03-11

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/552963A PH12023552963A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
CA3219079A1 (en) 2022-11-10
JOP20230276A1 (ar) 2023-11-02
BR112023023030A2 (pt) 2024-02-15
TW202313003A (zh) 2023-04-01
WO2022234457A1 (en) 2022-11-10
EP4333835A1 (en) 2024-03-13
CL2023003259A1 (es) 2024-05-31
CO2023015571A2 (es) 2023-11-30
AU2022268720A1 (en) 2023-12-21
UY39754A (es) 2022-11-30
IL308221A (en) 2024-01-01
JP2024516297A (ja) 2024-04-12
MX2023013040A (es) 2024-01-05
KR20240004857A (ko) 2024-01-11
PE20241784A1 (es) 2024-09-06

Similar Documents

Publication Publication Date Title
PH12023552963A1 (en) Compositions and methods for the treatment of depression
MX2022013417A (es) Inhibidores de fosfatidilinositol 3 cinasa (pi3k) alfa y metodos de uso de los mismos.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PT1933833E (pt) Terapia para o tratamento da bexiga superactiva
MX2024007933A (es) Anilinas de 2-pirazol y analogos relacionados para inhibir yap/taz-tead.
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
MX2024013762A (es) Inhibidores de fosfatidilinositol 3-cinasa alfa (pi3kalfa) y metodos de uso de los mismos
AR047719A1 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri
MX2021006985A (es) Metodos para el tratamiento de la depresión.
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
MX2011012596A (es) Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
MX2024008618A (es) Composiciones y métodos para el tratamiento de la depresión.
AR125762A1 (es) Composiciones y métodos para el tratamiento de la depresión
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.